Ratio de margen de beneficio neto
desde 2005
Cálculo
Vertex Pharmaceuticals Inc., ratio de margen de beneficio neto, tendencias a largo plazocálculo
| Ratio de margen de beneficio neto | = | 100 | × | Utilidad (pérdida) neta1 | ÷ | Ingresos1 | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2023 | 36.68% | = | 100 | × | 3,619,600) | ÷ | 9,869,200) |
| 31 dic. 2022 | 37.20% | = | 100 | × | 3,322,000) | ÷ | 8,930,700) |
| 31 dic. 2021 | 30.92% | = | 100 | × | 2,342,100) | ÷ | 7,574,400) |
| 31 dic. 2020 | 43.70% | = | 100 | × | 2,711,647) | ÷ | 6,205,683) |
| 31 dic. 2019 | 28.27% | = | 100 | × | 1,176,810) | ÷ | 4,162,821) |
| 31 dic. 2018 | 68.80% | = | 100 | × | 2,096,896) | ÷ | 3,047,597) |
| 31 dic. 2017 | 10.59% | = | 100 | × | 263,484) | ÷ | 2,488,652) |
| 31 dic. 2016 | -6.58% | = | 100 | × | (112,052) | ÷ | 1,702,177) |
| 31 dic. 2015 | -53.89% | = | 100 | × | (556,334) | ÷ | 1,032,336) |
| 31 dic. 2014 | -127.25% | = | 100 | × | (738,555) | ÷ | 580,415) |
| 31 dic. 2013 | -36.72% | = | 100 | × | (445,028) | ÷ | 1,211,975) |
| 31 dic. 2012 | -7.01% | = | 100 | × | (107,032) | ÷ | 1,527,042) |
| 31 dic. 2011 | 2.10% | = | 100 | × | 29,574) | ÷ | 1,410,626) |
| 31 dic. 2010 | -526.35% | = | 100 | × | (754,626) | ÷ | 143,370) |
| 31 dic. 2009 | -630.27% | = | 100 | × | (642,178) | ÷ | 101,889) |
| 31 dic. 2008 | -262.02% | = | 100 | × | (459,851) | ÷ | 175,504) |
| 31 dic. 2007 | -196.61% | = | 100 | × | (391,279) | ÷ | 199,012) |
| 31 dic. 2006 | -95.63% | = | 100 | × | (206,891) | ÷ | 216,356) |
| 31 dic. 2005 | -126.43% | = | 100 | × | (203,417) | ÷ | 160,890) |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
1 US$ en miles
Comparación con la competencia
Vertex Pharmaceuticals Inc., ratio de margen de beneficio neto, tendencias a largo plazo, comparación con los competidores
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic. 2023 | 36.68% | 8.95% | 24.96% | 17.83% | 15.36% | 21.03% | 41.28% | 0.61% | 3.62% | 30.14% | 13.99% |
| 31 dic. 2022 | 37.20% | 20.39% | 26.42% | 13.71% | 21.88% | 17.02% | 18.90% | 24.49% | 31.27% | 35.64% | 15.47% |
| 31 dic. 2021 | 30.92% | 20.54% | 24.25% | 15.08% | 19.71% | 23.05% | 22.26% | 26.79% | 27.04% | 50.25% | 19.70% |
| 31 dic. 2020 | 43.70% | 10.08% | 29.97% | -21.20% | 25.24% | 0.51% | 17.82% | 14.72% | 22.95% | 41.35% | 19.79% |
| 31 dic. 2019 | 28.27% | 23.69% | 35.32% | 13.15% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% |
| 31 dic. 2018 | 68.80% | 17.36% | 37.25% | 21.81% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% |
| 31 dic. 2017 | 10.59% | 18.82% | 9.08% | 4.85% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% |
| 31 dic. 2016 | -6.58% | 23.22% | 35.27% | 22.94% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% |
| 31 dic. 2015 | -53.89% | 22.50% | 33.13% | 9.45% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% |
| 31 dic. 2014 | -127.25% | 8.89% | 26.69% | 12.62% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% |
| 31 dic. 2013 | -36.72% | 21.97% | 27.93% | 15.64% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% |
| 31 dic. 2012 | -7.01% | 28.70% | 26.11% | 11.12% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% |
| 31 dic. 2011 | 2.10% | — | 24.08% | 17.46% | 17.90% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% |
| 31 dic. 2010 | -526.35% | — | 31.56% | 15.92% | 21.97% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% |
| 31 dic. 2009 | -630.27% | — | 32.09% | 56.42% | 19.82% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% |
| 31 dic. 2008 | -262.02% | — | 28.57% | 25.47% | -10.17% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% |
| 31 dic. 2007 | -196.61% | — | 22.12% | 11.19% | 15.85% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% |
| 31 dic. 2006 | -95.63% | — | 21.29% | 8.85% | 16.97% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% |
| 31 dic. 2005 | -126.43% | — | 30.56% | 15.62% | 13.52% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparación con el sector industrial: Productos farmacéuticos, biotecnología y ciencias de la vida
Vertex Pharmaceuticals Inc., ratio de margen de beneficio neto, tendencias a largo plazo, comparación con el sector industrial: productos farmacéuticos, biotecnología y ciencias de la vida
| Vertex Pharmaceuticals Inc. | Productos farmacéuticos, biotecnología y ciencias de la vida | |
|---|---|---|
| 31 dic. 2023 | 36.68% | 17.47% |
| 31 dic. 2022 | 37.20% | 22.30% |
| 31 dic. 2021 | 30.92% | 23.40% |
| 31 dic. 2020 | 43.70% | 13.47% |
| 31 dic. 2019 | 28.27% | 23.50% |
| 31 dic. 2018 | 68.80% | 19.76% |
| 31 dic. 2017 | 10.59% | 13.05% |
| 31 dic. 2016 | -6.58% | 21.24% |
| 31 dic. 2015 | -53.89% | 21.78% |
| 31 dic. 2014 | -127.25% | 22.11% |
| 31 dic. 2013 | -36.72% | 22.82% |
| 31 dic. 2012 | -7.01% | 19.04% |
| 31 dic. 2011 | 2.10% | 15.90% |
| 31 dic. 2010 | -526.35% | 15.56% |
| 31 dic. 2009 | -630.27% | 26.87% |
| 31 dic. 2008 | -262.02% | 18.88% |
| 31 dic. 2007 | -196.61% | 16.31% |
| 31 dic. 2006 | -95.63% | 22.95% |
| 31 dic. 2005 | -126.43% | 18.78% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparación con la industria: Atención médica
Vertex Pharmaceuticals Inc., ratio de margen de beneficio neto, tendencias a largo plazo, comparación con la industria: atención médica
| Vertex Pharmaceuticals Inc. | Atención médica | |
|---|---|---|
| 31 dic. 2023 | 36.68% | 7.95% |
| 31 dic. 2022 | 37.20% | 10.17% |
| 31 dic. 2021 | 30.92% | 10.82% |
| 31 dic. 2020 | 43.70% | 7.69% |
| 31 dic. 2019 | 28.27% | 10.13% |
| 31 dic. 2018 | 68.80% | 9.17% |
| 31 dic. 2017 | 10.59% | 7.75% |
| 31 dic. 2016 | -6.58% | 9.91% |
| 31 dic. 2015 | -53.89% | 10.98% |
| 31 dic. 2014 | -127.25% | 11.39% |
| 31 dic. 2013 | -36.72% | 11.99% |
| 31 dic. 2012 | -7.01% | 11.19% |
| 31 dic. 2011 | 2.10% | 10.02% |
| 31 dic. 2010 | -526.35% | 10.09% |
| 31 dic. 2009 | -630.27% | 14.33% |
| 31 dic. 2008 | -262.02% | 10.62% |
| 31 dic. 2007 | -196.61% | 10.58% |
| 31 dic. 2006 | -95.63% | 13.20% |
| 31 dic. 2005 | -126.43% | 12.89% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).